



AGENIX LIMITED
11 Durbell Street
Acacia Ridge QLD 4110
Australia
www.agenix.com

ASX MEDIA RELEASE

10 September, 2008

Australian patent granted for ThromboView® technology

Agenix Limited has pleasure in announcing the ThromboView technology has been granted an Australian patent.

This grant follows from the very recent award of a New Zealand patent, adding to the expanding ThromboView® patent estate already granted in the United States and Singapore. Further world-wide applications are under examination and Agenix continues to vigorously pursue protection for its proprietary intellectual property.

“We are pleased that the ThromboView technology continues to be recognized and protected on a global level”, said CEO and Managing Director, Dr. Stephen Phua.

The clot-targeting capabilities of hu3B6 are currently being exploited in the ThromboView product format which utilizes technetium-99m, a common radioisotope used in nuclear medicine, to image blood clots in both the deep veins of the legs and the pulmonary vasculature.

Jeffrey Luckins

Company Secretary

END

SOURCE: Agenix Ltd, Brisbane, Australia

CONTACT: Dr Stephen Phua - Chief Executive Officer

Ph: +65 68465152 or email sphua@agenix.com